Accenture Earnings Show AI Bookings Lift

Accenture earnings show AI-driven bookings pushed revenue to the top of guidance and confirmed fiscal 2026 targets, shaping near-term trader positioning.

December 18, 2025·2 min read
View all news articles
Flat vector consulting briefcase with expanding circuit to symbolize Accenture earnings and AI bookings strength.

KEY TAKEAWAYS

  • Revenue was $18.7B, at the top of the quarter's guided range.
  • New bookings totaled $20.9B, including $2.2B of advanced AI bookings.
  • Company confirmed fiscal 2026 guidance and narrowed GAAP EPS to $13.12-$13.50.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Accenture earnings showed revenue at the top of the company’s guided range as AI demand drove robust bookings, and management narrowed the GAAP EPS outlook while confirming fiscal 2026 revenue and margin targets.

Quarter Results and Bookings

Accenture reported revenue of $18.74 billion for the quarter ended November 30, 2025, a 6% increase in U.S. dollars and 5% in local currency from the prior year, reaching the top of its guided range. New bookings rose 12% in U.S. dollars to $20.9 billion, including $2.2 billion from advanced AI projects. Thirty-three clients recorded quarterly bookings exceeding $100 million. The company disclosed these results in a press release on December 18 at 6:39 a.m. ET.

Revenue growth varied across industries. Products led with $5.74 billion, up 6%. Communications, Media & Technology generated $3.10 billion, up 9%. Financial Services rose 14% to $3.60 billion. Health and Public Service held steady at $3.80 billion, while Resources increased 3% to $2.50 billion.

Margins, Profitability, and Outlook

GAAP operating income declined 3% to $2.87 billion, with the GAAP operating margin narrowing 140 basis points to 15.3%. Adjusted operating income rose to $3.18 billion, lifting the adjusted margin by 30 basis points to 17.0%. GAAP diluted earnings per share fell 1% to $3.54, while adjusted diluted EPS increased 10% to $3.94, excluding $0.40 in business-optimization costs. Free cash flow totaled $1.5 billion.

For the second quarter, Accenture set revenue guidance between $17.35 billion and $18.0 billion, implying 1% to 5% local-currency growth and a roughly 3.5% foreign-exchange tailwind. The company confirmed fiscal 2026 guidance with revenue growth of 2% to 5% in local currency, or about 3% to 6% excluding a 1% impact from U.S. federal business. Adjusted operating margin is targeted at 15.7% to 15.9%, reflecting a 10 to 30 basis-point expansion over fiscal 2025, excluding business-optimization costs. The annual effective tax rate is expected between 23.5% and 25.5%. GAAP diluted EPS guidance narrowed to $13.12 to $13.50, with adjusted EPS set at $13.52 to $13.90. The company returned $3.3 billion to shareholders in the quarter, including $2.3 billion in share repurchases.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

Apple CEO John Ternus Faces Siri and Talent Tests

Apple CEO John Ternus Faces Siri and Talent Tests

Apple CEO John Ternus faces an early iPhone launch and a Siri overhaul that traders will watch for signals on product cadence and talent risk.

Charter Q1 2026 Results Signal Weak Broadband

Charter Q1 2026 Results Signal Weak Broadband

Charter Q1 2026 results show revenue decline and larger-than-expected broadband losses that produced an EPS miss and complicate capital plans.

Google to Invest in Anthropic in Up to $40B Deal

Google to Invest in Anthropic in Up to $40B Deal

Google to Invest in Anthropic reshapes private AI valuations and cloud ties; a $10B initial and up-to-$40B pledge alters private-market pricing.

X-Energy IPO Debuts on Nasdaq

X-Energy IPO Debuts on Nasdaq

X-Energy IPO set a strong Nasdaq open after an upsized, heavily subscribed offering, boosting early valuation and concentrating near-term trader flows.

Regeneron MFN Deal Lowers Prices, Offers Free Gene Therapy

Regeneron MFN Deal Lowers Prices, Offers Free Gene Therapy

Regeneron MFN deal cuts U.S. drug prices and offers Otarmeni free while securing tariff relief, and may push investors to reprice launch economics.

Tesla Cybercab Production Begins at Gigafactory Texas

Tesla Cybercab Production Begins at Gigafactory Texas

Tesla Cybercab production shifts robotaxi revenue timing and positioning as company cites $0.20 per mile economics and sub-$30,000 price targets.